Skip to main content

Table 2 Characteristics* of the patients successfully genotyped (N = 57)

From: Low levels of HIV-1 drug resistance mutations in patients who achieved viral re-suppression without regimen switch: a retrospective study

CategoryParametersCharacteristicsTotal [N (% or IQR)]#P-Values
DemographicsSexFemale39 (68)0.042
Male18 (32)
Age at baselineMedian (IQR) years34 (30–42)0.921
Marital StatusSingle12 (21)0.663
Married29 (51)
Divorced/Separated4 (7)
Widowed12 (21)
EducationNone6 (11)0.770
Primary14 (25)
Secondary18 (32)
Tertiary19 (33)
OccupationNot Employed15 (26)0.338
Employed42 (74)
Clinical ParametersFirst-line Backbone NRTIAZT34 (60)0.978
TDF16 (28)
bOthers7 (12)
First-line Second NRTI3TC39 (68)0.666
FTC18 (32)
First-line NNRTINVP43 (75)0.071
EFV14 (25)
Time on First-line ART (Months)ART Initiation to F121 (12–36)0.217
F1 to FC5 (4–6)0.086
FC to Viral Re-suppression5 (3–10)0.118
Laboratory ParametersBaseline CD4+ cells/μL< 20038 (67)0.780
200–35017 (30)
> 3502 (4)
Median (IQR)155 (105–235)
Baseline Viral Load (VL), copies/mL≤100,00036 (63)0.774
> 100,00018 (32)
Unknown3 (5)
Median (IQR)43,587 (13128–176,990)
VL at initial failure (copies/mL)Median (IQR)9113 (3680–49,670)0.768
VL at confirmatory failure (copies/mL)Median (IQR)16,266 (2042–4,002,513)0.454
HIV-1 SubtypeG25 (44)0.261
Grouped as G, CRF02_AG and Others
CRF02_AG23 (40)
A3 (5)
CRF06_cpx3 (5)
J1 (2)
C1 (2)
Recombinant of A1, G1 (2)
  1. aDemographic characteristics of those successfully genotyped were not significantly different from those not genotyped; F1 First VL ≥ 1000 cp/mL; FC Second VL ≥ 1000 cp/mL. #P-value is for difference in patient characteristic and drug resistance. IQR Interquartile range. bOthers = Backbone NRTI was switched